Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o

Actuate Therapeutics (ACTU) announced positive topline results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC), demonstrating a statistically significant and clinically meaningful increase in median overall survival (10.1 months vs 7.2 months, HR=0.63, p=0.01) and a 37% reduction in the risk of death compared to GnP alone; the company plans to engage with the FDA in the second half of 2025 to discuss a path toward product registration.

Analysis

Actuate Therapeutics (NASDAQ: ACTU) has reported highly encouraging topline results from its Phase 2 Actuate-1801 Part 3B trial for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial successfully met its primary endpoint, demonstrating a clinically meaningful and statistically significant increase in median overall survival (mOS) to 10.1 months for the elraglusib/GnP arm compared to 7.2 months for GnP alone (log-rank p=0.01). This represents a 37% reduction in the risk of death (HR=0.63). Furthermore, the 12-month survival rate nearly doubled, reaching 44.1% for the combination therapy versus 22.3% for GnP alone, with sustained survival benefits observed at eighteen months (19.7% vs 4.4%) and twenty-four months (13.8% vs 0%). The elraglusib/GnP combination also showed numerically improved overall response rates (29.0% vs 21.8%), median progression-free survival (5.6 months vs 5.1 months), and median duration of response (5.5 months vs 4.0 months). Crucially, the safety profile was favorable, with treatment-emergent adverse events in the combination arm similar to the GnP arm, and most treatment-related adverse events being Grade 1-2, primarily transient visual impairments. Exploratory biomarker analysis supported elraglusib's proposed immune-modulating mechanism. Actuate plans to engage with the FDA and EMA in the second half of 2025 to discuss the path to registration. However, the company's forward-looking statements highlight a critical financial consideration: it requires additional capital to finance operations beyond the second quarter of fiscal year 2025, raising substantial doubt about its ability to continue as a going concern without securing further funding.

Key Decisions for Investors

• The positive Phase 2 data for elraglusib represents a significant clinical de-risking event and a potential advancement in mPDAC treatment, a high unmet medical need, warranting close attention to Actuate's upcoming regulatory interactions.
• Investors should monitor the outcomes of the planned FDA and EMA discussions in H2 2025, as these will be critical catalysts determining the future development pathway, timeline, and commercial potential of elraglusib.
• Despite the promising clinical results, the company's disclosed need for additional capital beyond Q2 2025 introduces significant financing risk and potential for shareholder dilution, which must be carefully weighed against the drug's clinical and regulatory prospects.